Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors

Reuters12-17 19:00

<a href="https://laohu8.com/S/PSNL">Personalis</a> Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors

Personalis Inc. has announced the publication of a new clinical study in the journal Clinical Cancer Research, evaluating the use of its ultra-sensitive, tumor-informed molecular residual disease (MRD) assay, NeXT Personal®, for monitoring cancer immunotherapy response across a range of solid tumors. The study, led by Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, analyzed 202 patients with stage IV solid tumors across 24 cancer types treated with immune checkpoint inhibitors and other immunotherapies. Key findings include high sensitivity of the test, with ctDNA detected in 98% of patients at baseline, and the prognostic value of early ctDNA dynamics. Patients who achieved durable molecular clearance of ctDNA for at least 180 days had 100% overall survival in the study, while early increases in ctDNA were associated with poor response to immunotherapy. The results have been published and are now available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217599767) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592991819?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592991819","market":"fut","top_or_hot":-1,"title":"Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Personalis Inc. has announced the publication of a new clinical study in the journal Clinical Cancer Research, evaluating the use of its ultra-sensitive, tumor-informed molecular residual disease (MRD) assay, NeXT Personal®, for monitoring cancer immunotherapy response across a range of solid tumors. The study, led by Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, analyzed 202 patients with stage IV solid tumors across 24 cancer types treated with immune checkpoint inhibitors and other immunotherapies. Key findings include high sensitivity of the test, with ctDNA detected in 98% of patients at baseline, and the prognostic value of early ctDNA dynamics. Patients who achieved durable molecular clearance of ctDNA for at least 180 days had 100% overall survival in the study, while early increases in ctDNA were associated with poor response to immunotherapy. The results have been published and are now available.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217599767) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPersonalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Personalis Inc. has announced the publication of a new clinical study in the journal Clinical Cancer Research, evaluating the use of its ultra-sensitive, tumor-informed molecular residual disease (MRD) assay, NeXT Personal®, for monitoring cancer immunotherapy response across a range of solid tumors. The study, led by Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, analyzed 202 patients with stage IV solid tumors across 24 cancer types treated with immune checkpoint inhibitors and other immunotherapies. Key findings include high sensitivity of the test, with ctDNA detected in 98% of patients at baseline, and the prognostic value of early ctDNA dynamics. Patients who achieved durable molecular clearance of ctDNA for at least 180 days had 100% overall survival in the study, while early increases in ctDNA were associated with poor response to immunotherapy. The results have been published and are now available.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217599767) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSNL","symbol_name":"Personalis","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9GzBDd:1","article_id":"2592991819","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592991819","pubTimestamp":1765969234,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Personalis Inc. has announced the publication of a new clinical study in the journal Clinical Cancer Research, evaluating the use of its ultra-sensitive, tumor-informed molecular residual disease  assay, NeXT Personal, for monitoring cancer immunotherapy response across a range of solid tumors. The study, led by Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology  in Barcelona, analyzed 202 patients with stage IV solid tumors across 24 cancer types treated with immune checkpoint inhibitors and other immunotherapies. Key findings include high sensitivity of the test, with ctDNA detected in 98% of patients at baseline, and the prognostic value of early ctDNA dynamics. Patients who achieved durable molecular clearance of ctDNA for at least 180 days had 100% overall survival in the study, while early increases in ctDNA were associated with poor response to immunotherapy. The results have been published and are now available.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSNL":"Personalis","BK4121":"生命科学工具和服务"},"translate_title":"Personalis研究显示超灵敏ctDNA测试可预测实体瘤的免疫治疗结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":0.9},"content_text":"Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors\n    \n\n        Personalis Inc. has announced the publication of a new clinical study in the journal Clinical Cancer Research, evaluating the use of its ultra-sensitive, tumor-informed molecular residual disease (MRD) assay, NeXT Personal®, for monitoring cancer immunotherapy response across a range of solid tumors. The study, led by Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, analyzed 202 patients with stage IV solid tumors across 24 cancer types treated with immune checkpoint inhibitors and other immunotherapies. Key findings include high sensitivity of the test, with ctDNA detected in 98% of patients at baseline, and the prognostic value of early ctDNA dynamics. Patients who achieved durable molecular clearance of ctDNA for at least 180 days had 100% overall survival in the study, while early increases in ctDNA were associated with poor response to immunotherapy. The results have been published and are now available.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217599767) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592991819","isCrawlerRequest":true}